The Pittsburgh Business Times announced today that Charlie Batch’s company, Impellia, has signed a license for a University of Pittsburgh-developed technology known as PIVOT. Developed by researchers at UPMC Sports Medicine, it assesses stability of the knee’s anterior cruciate ligament (ACL) and determines how significant an ACL injury is.
“We are extremely excited about the market potential of PIVOT,” said Batch in a statement. “Through our team’s growth-oriented approach, extensive domain expertise, and sales network, we have the means to build a broad platform for the technology. We are thrilled that the Innovation Institute has recognized our ability to execute significant marketing strategies and bring real-world applications to its technologies.”
Read the full story here.
